Back to results
US 9,822,353 B2Granted
PEGylated aspartyl-tRNA synthetase polypeptides
AssigneeaTyr Pharma, Inc.
InventorsYing Ji Buechler, Chi-Fang Wu, Jeffrey Greve, John D. Mendlein
Life of this patent
Estimating the term…
Abstract
The present invention provides PEGylated aspartyl-tRNA synthetase (DRS) polypeptides, compositions comprising the same, and methods of using such polypeptides and compositions for treating or diagnosing a variety of conditions. The PEGylated DRS polypeptides of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic properties compared to non-PEGylated DRS polypeptides.
Claims9
A PEGylated aspartyl-tRNA synthetase (DRS) polypeptide selected from,
- (a) a DRS polypeptide consisting of a sequence that is at least 95% identical to the sequence set forth in SEQ ID NO:3 DRS(1-154), which is modified by C76S substitution, where a maleimide monomethoxy polyethylene glycol (mPEG) derivative of about 40,000 Daltons is covalently attached via a thio ether linkage to C130;
- and
- (b) a DRS polypeptide of up to 200 amino acids in length comprising a sequence that is at least 95% identical to the sequence set forth in SEQ ID NO:3 DRS(1-154), which is modified by C76S substitution, where a maleimide monomethoxy polyethylene glycol (mPEG) derivative of about 40,000 Daltons is covalently attached via a thio ether linkage to C130.
Dependencies are inferred from the claim text.